Abstract
Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
Highlights
Chronic hepatitis B (CHB) is one of the most common causes of chronic liver disease, with over 250 million people infected worldwide, accounting for 60% of hepatocellular carcinoma (HCC) cases in Asia and Africa and 20% of cases in the West[1,2,3,4,5]
We summarize recent evidence comparing the effectiveness of these two treatments from the perspective that tenofovir disoproxil fumarate (TDF) may be superior to ETV in preventing HCC development
The lower risk of HCC in the TDF group was not observed in the subgroup analysis of patients with compensated cirrhosis at baseline to further exclude patients with decompensated cirrhosis or patients who were enrolled after 2011 to minimize the follow-up duration between the two groups[19]. Another single-center study including 404 treatment-naïve patients with CHB from Korea observed that TDF treatment was associated with a significantly lower risk of HCC compared with ETV in multivariable analysis, which was consistently observed in the propensity score (PS)-matching analysis[15]
Summary
Chronic hepatitis B (CHB) is one of the most common causes of chronic liver disease, with over 250 million people infected worldwide, accounting for 60% of hepatocellular carcinoma (HCC) cases in Asia and Africa and 20% of cases in the West[1,2,3,4,5]. A multicenter retrospective study of 1560 cirrhotic patients from Taiwan reported that TDF significantly decreased the risk of HCC compared with ETV (aHR = 0.67; 95%CI: 0.48-0.93; P = 0.002), which was consistently observed in PS-matching analysis and PS-weighting analysis[19].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
